Award

Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill Women – A Randomised Controlled Trial (Bone Zone)

Description: Women over 50 years of age are at high risk of osteoporosis and fragility fractures after life-threatening critical illness. There are effective medications to prevent this, however few women receive them during critical illness. This study aims to test 2 commonly used anti-fracture medications in 450 critically ill women over 50-years of age in Australia. If shown to be effective, this could transform clinical practice, and the recognition and prevention of bone loss in critically ill women.
Amount: A$1,905,000
Funding type: grant
Funder scheme: 2019 Rare Cancers, Rare Diseases and Unmet Need - General
Start date: 2020-06-01
End date: 2027-05-31
Investigator: Neil Orford (lead)
Institution: Monash University
Field: Medicine
Funded outputs count: 0
Funder award ID: MRF1199726
OpenAlex ID: G4306571996